• Team
  • Approach
  • Portfolio
  • News
  • Blog
  • Contact
  • Investor Login
  • Team
  • Approach
  • Portfolio
  • News
  • Blog
  • Investor Login

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease… Read More

FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

– COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy –… Read More

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene’s anti-PD-1 antibody tislelizumab BOSTON & CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–Feb. 17, 2021– Boston Immune Technologies and Therapeutics,… Read More

BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other… Read More

Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a… Read More

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight… Read More

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the… Read More

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

– Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments – – Kymera to retain option during clinical development… Read More

Shattuck Labs Announces Closing of $118 Million Series B Financing

  Financing will advance two ARC™ clinical programs and expand pipeline development —   DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck… Read More

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046… Read More

  • Team
  • Approach
  • Portfolio
  • News
  • Blog
  • Contact
  • Investor Login